

# Harry David Wilson

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3920744/harry-david-wilson-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

20  
papers

1,215  
citations

10  
h-index

23  
g-index

23  
ext. papers

1,728  
ext. citations

11  
avg, IF

3.85  
L-index

#	Paper	IF	Citations
20	Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. <i>Nature Microbiology</i> , <b>2020</b> , 5, 1598-1607	26.6	667
19	Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection		146
18	Resistance of Transmitted Founder HIV-1 to IFITM-Mediated Restriction. <i>Cell Host and Microbe</i> , <b>2016</b> , 20, 429-442	23.4	115
17	Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings. <i>PLoS Pathogens</i> , <b>2020</b> , 16, e1008817	7.6	72
16	KHNYN is essential for the zinc finger antiviral protein (ZAP) to restrict HIV-1 containing clustered CpG dinucleotides. <i>ELife</i> , <b>2019</b> , 8,	8.9	66
15	CpG Dinucleotides Inhibit HIV-1 Replication through Zinc Finger Antiviral Protein (ZAP)-Dependent and -Independent Mechanisms. <i>Journal of Virology</i> , <b>2020</b> , 94,	6.6	38
14	Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern. <i>Nature Microbiology</i> , <b>2021</b> , 6, 1433-1442	26.6	32
13	Resilient SARS-CoV-2 diagnostics workflows including viral heat inactivation <b>2021</b> ,		15
12	Real-world evaluation of a novel technology for quantitative simultaneous antibody detection against multiple SARS-CoV-2 antigens in a cohort of patients presenting with COVID-19 syndrome. <i>Analyst, The</i> , <b>2020</b> , 145, 5638-5646	5	14
11	Resilient SARS-CoV-2 diagnostics workflows including viral heat inactivation. <i>PLoS ONE</i> , <b>2021</b> , 16, e0256813	3.7	11
10	Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings		10
9	Combined epidemiological and genomic analysis of nosocomial SARS-CoV-2 infection early in the pandemic and the role of unidentified cases in transmission. <i>Clinical Microbiology and Infection</i> , <b>2021</b> ,	9.5	7
8	The P681H mutation in the Spike glycoprotein confers Type I interferon resistance in the SARS-CoV-2 alpha (B.1.1.7) variant		6
7	Antibody longevity and cross-neutralizing activity following SARS-CoV-2 wave 1 and B.1.1.7 infections <b>2021</b> ,		5
6	Combined epidemiological and genomic analysis of nosocomial SARS-CoV-2 transmission identifies community social distancing as the dominant intervention reducing outbreaks		3
5	Clinical utility of targeted SARS-CoV-2 serology testing to aid the diagnosis and management of suspected missed, late or post-COVID-19 infection syndromes: Results from a pilot service implemented during the first pandemic wave. <i>PLoS ONE</i> , <b>2021</b> , 16, e0249791	3.7	3
4	Skewing of the CD4(+) T-cell pool toward monofunctional antigen-specific responses in patients with immune reconstitution inflammatory syndrome in The Gambia. <i>Clinical Infectious Diseases</i> , <b>2013</b> , 57, 594-603	11.6	2

3	Clinical utility of targeted SARS-CoV-2 serology testing to aid the diagnosis and management of suspected missed, late or post-COVID-19 infection syndromes: results from a pilot service		2
2	TRIM25 and ZAP target the Ebola virus ribonucleoprotein complex to mediate interferon-induced restriction.. <i>PLoS Pathogens</i> , <b>2022</b> , 18, e1010530	7.6	0
1	Minimal impact of ZAP on lentiviral vector production and transduction efficiency. <i>Molecular Therapy - Methods and Clinical Development</i> , <b>2021</b> , 23, 147-157	6.4	